Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 7/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6806379 | 1.00 | ALDH1A1 (0.45) | ALDH1A1CYP3A4TSHRMAPK1TDP1 | |
| SCHEMBL6806362 | 0.94 | MME (0.46) | ALDH1A1MME | |
| SCHEMBL6804184 | 0.91 | MME (0.46) | ALDH1A1MME | |
| SCHEMBL6804195 | 0.91 | MME (0.46) | ALDH1A1MME | |
| SCHEMBL8335047 | 0.87 | MME (0.56) | MME | |
| SCHEMBL6807982 | 0.84 | MME (0.45) | MME | |
| SCHEMBL5925056 | 0.84 | MME (0.49) | ALDH1A1MMECTSLCTSB | |
| SCHEMBL9753833 | 0.84 | MME (0.49) | ALDH1A1MMECTSLCTSB | |
| SCHEMBL5796118 | 0.83 | MME (0.48) | ALDH1A1MMECTSLCTSB | |
| SCHEMBL6268697 | 0.81 | MME (0.42) | ALDH1A1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138274-A1 | Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders | DACK KEVIN NEIL (GB) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138274-A1 | Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders | MME, ECE1, ECE2 | ALDH1A1 714/4885CYP3A4 1589/4885TSHR 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.